Form 4: ClearPoint Neuro Executive Jeremy Stigall Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
ClearPoint Neuro's Chief Business Officer, Jeremy Stigall, disposed of 420 shares of common stock to cover tax obligations related to vesting restricted stock.
Summary
- On August 20, 2024, Jeremy L. Stigall, Chief Business Officer of ClearPoint Neuro, Inc., disposed of 420 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations related to the vesting of restricted stock.
- The shares were sold at a price of $11.26 per share.
- Following the transaction, Stigall directly owns 48,272 shares of ClearPoint Neuro, Inc.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock transaction for tax purposes. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This transaction is related to tax obligations, which is a common reason for stock sales by executives.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of transaction: Jeremy Stigall disposed of 420 shares of common stock. |
| 08/21/2024 | Date of report: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.